57946-60-8

Basic information

• Product Name: 2-(2,2,2-TRIFLUOROETHOXY)ANILINE
• Synonyms: BenzenaMine,2-(2,2,2-trifluoroethoxy)-;2-(2,2,2-Trifluoroethoxy)-benzenaMine;2-Amino-beta,beta,beta-trifluorophenetole;2-(Trifluoroethoxy)aniline;2-(2,2,2-Trifluoro-ethoxy)-phenylamine;2-(2,2,2-Trifluoroethoxy)aniline97%
• CAS NO: 57946-60-8
• Molecular Formula: C₈H₈F₃NO
• Molecular Weight: 191.1504
• Mol File: 57946-60-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 49.0 to 53.0 °C
• Boiling Point: 214.9 °C at 760 mmHg
• Flash Point: 83.8 °C
• Appearance: /
• Density: 1.286 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2,2,2-TRIFLUOROETHOXY)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,2,2-TRIFLUOROETHOXY)ANILINE(57946-60-8)
• EPA Substance Registry System: 2-(2,2,2-TRIFLUOROETHOXY)ANILINE(57946-60-8)

Safety Data

• Hazardous Substances Data: 57946-60-8(Hazardous Substances Data)

Usage

Description

2-(2,2,2-TRIFLUOROETHOXY)ANILINE is an organic compound characterized by the presence of a trifluoroethoxy group attached to an aniline molecule. 2-(2,2,2-TRIFLUOROETHOXY)ANILINE is known for its unique chemical properties and potential applications in various industries.

Uses

Used in Pharmaceutical Industry:
2-(2,2,2-TRIFLUOROETHOXY)ANILINE is used as a reactant for the preparation of 1,4-diarylpiperidinylmethylureas, which are anti-hyperlipidemic agents. These agents play a crucial role in the treatment and management of hyperlipidemia, a condition characterized by high levels of lipids in the blood, which can lead to cardiovascular diseases.
The use of 2-(2,2,2-TRIFLUOROETHOXY)ANILINE in the pharmaceutical industry is primarily due to its ability to contribute to the synthesis of compounds with potential therapeutic effects. Its unique structure allows for the development of new drugs that can help address various health concerns, particularly those related to lipid metabolism and cardiovascular health.

Upstream product

• 87014-28-6 1-(2,2,2-trifluoroethoxy)-2-nitrobenzene 
• 88-75-5 2-hydroxynitrobenzene 
• 433-06-7 2,2,2-Trifluoroethyl p-toluenesulfonate 
• 7439-89-6 iron 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 178671-99-3 1-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 
• 334930-13-1 1-(3-Aminopropyl)-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 
• 334930-12-0 1-[2-(2,2,2-trifluoroethoxy)-phenyl]-4-[3-(N-phthalimido)-propyl]-piperazine 
• 1025909-31-2 8-Chloro-4-(3-{4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propylamino)-quinoline-3-carboxylic acid 
• 1027544-70-2 8-Chloro-4-(3-{4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propylamino)-quinoline-3-carboxylic acid ethyl ester 
• 220383-36-8 1-[N-[2-(2,2,2-trifluoroethoxy)-phenyl]-2-aminoethyl]-4-(2-methoxyphenyl)-piperazine 
• 917514-08-0 4-heptafluoroisopropyl-2-(2,2,2-trifluoroethoxy)aniline 
• 1143579-12-7 4-(3-methoxyphenyl)-1-[2-(2,2,2-trifluoroethoxy)phenyl]piperidine-4-carbonitrile 

Relevant articles and documents

BIARYL-CONTAINING COMPOUNDS AS INVERSE AGONISTS OF ROR-GAMMA RECEPTORS

The present invention relates to biaryl-containing inverse agonists of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these biaryl- containing inverse agonists, and methods of modulating ROR-gamma receptors using these inverse agonists. Also provided are methods of using biaryl-containing inverse agonists to treat ROR-gamma mediated diseases.

PYRROLO 3,2-c]QUINOLINE DERIVATIVES CONTAINING HALOALKOXY GROUP AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention relates to a novel pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group, represented by Formula I, their pharmaceutically acceptable salts; process for preparation thereof; and pharmaceutical composition thereof for treati

PYRIMIDINEDIONE, PYRIMIDINETRIONE, TRIAZINEDIONE AND TETRAHYDROQUINAZOLINEDIONE DERIVATIVES AS ALPHA1-ADRENERGIC RECEPTOR ANTAGONISTS

Compounds of Formula I: STR1 where R 5 is a group selected from Formulae (a), (b), (c) and (d): STR2 and the pharmaceutically acceptable salts and N-oxides thereof, are α 1-adrenergic receptor antagonists useful for the treatment of diseases involving directly or indirectly an obstruction of the lower urinary tract, such as benign prostatic hyperplasia.